{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:05:41Z","timestamp":1789506341380,"version":"build-2803163510"},"reference-count":20,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2022,8,1]]},"DOI":"10.1001\/jamadermatol.2022.2149","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T15:35:43Z","timestamp":1655912143000},"page":"893","source":"Crossref","is-referenced-by-count":9,"title":["Evaluation of Clinical Relevance and Biological Effects of Antirituximab Antibodies in Patients With Pemphigus"],"prefix":"10.1001","volume":"158","author":[{"given":"Alexandre","family":"Lemieux","sequence":"first","affiliation":[{"name":"Department of Dermatology, Normandie University, Universit\u00e9 de Rouen, Inserm U1234, CHU Rouen, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Maho-Vaillant","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Normandie University, Universit\u00e9 de Rouen, Inserm U1234, CHU Rouen, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Golinski","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Normandie University, Universit\u00e9 de Rouen, Inserm U1234, CHU Rouen, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivien","family":"H\u00e9bert","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Normandie University, Universit\u00e9 de Rouen, Inserm U1234, CHU Rouen, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Boyer","sequence":"additional","affiliation":[{"name":"Department of Immunology, Normandie University, Universit\u00e9 de Rouen, Inserm U1234, CHU Rouen, Rouen, France"},{"name":"Normandie University, Universit\u00e9 de Rouen, Inserm U1234, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Calbo","sequence":"additional","affiliation":[{"name":"Normandie University, Universit\u00e9 de Rouen, Inserm U1234, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Candon","sequence":"additional","affiliation":[{"name":"Department of Immunology, Normandie University, Universit\u00e9 de Rouen, Inserm U1234, CHU Rouen, Rouen, France"},{"name":"Normandie University, Universit\u00e9 de Rouen, Inserm U1234, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Joly","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Normandie University, Universit\u00e9 de Rouen, Inserm U1234, CHU Rouen, Rouen, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10083","key":"doi220027r1","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"issue":"24","key":"doi220027r2","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa2028564","article-title":"Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris.","volume":"384","author":"Werth","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"doi220027r3","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1001\/jamadermatol.2017.5176","article-title":"Rituximab as single long-term maintenance therapy in patients with difficult-to-treat pemphigus.","volume":"154","author":"Sanchez","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"175","key":"doi220027r4","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005166","article-title":"Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response.","volume":"5","author":"Colliou","year":"2013","journal-title":"Sci Transl Med"},{"issue":"5","key":"doi220027r5","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1001\/jamadermatol.2020.0290","article-title":"Factors associated with short-term relapse in patients with pemphigus who receive rituximab as first-line therapy: a post hoc analysis of a randomized clinical trial.","volume":"156","author":"Mignard","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"12","key":"doi220027r6","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1001\/jamadermatol.2019.3236","article-title":"Factors associated with complete remission after rituximab therapy for pemphigus.","volume":"155","author":"Kushner","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"3","key":"doi220027r7","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.clim.2009.05.007","article-title":"Immunogenicity of rituximab in patients with severe pemphigus.","volume":"132","author":"Schmidt","year":"2009","journal-title":"Clin Immunol"},{"issue":"3","key":"doi220027r8","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jaci.2012.03.022","article-title":"Inhibitory human antichimeric antibodies to rituximab in a patient with pemphigus.","volume":"130","author":"Lunardon","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"doi220027r9","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00467-021-05069-w","article-title":"Anti-rituximab antibodies in pediatric steroid-dependent nephrotic syndrome.","volume":"37","author":"Bertrand","year":"2022","journal-title":"Pediatr Nephrol"},{"issue":"12","key":"doi220027r10","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1136\/ard.2007.083162","article-title":"Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.","volume":"67","author":"Albert","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"doi220027r11","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1136\/ard.2009.109041","article-title":"Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis.","volume":"69","author":"Thurlings","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"doi220027r12","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus.","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi220027r13","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40120-018-0101-4","article-title":"Only follow-up of memory B cells helps monitor rituximab administration to patients with neuromyelitis optical spectrum disorders.","volume":"7","author":"Lebrun","year":"2018","journal-title":"Neurol Ther"},{"issue":"8","key":"doi220027r15","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1002\/(ISSN)1529-0131","article-title":"B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab.","volume":"50","author":"Looney","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"1","key":"doi220027r16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/BF02982552","article-title":"Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody.","volume":"74","author":"Maeda","year":"2001","journal-title":"Int J Hematol"},{"issue":"4","key":"doi220027r17","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1080\/19420862.2015.1048411","article-title":"Cross-reactive and pre-existing antibodies to therapeutic antibodies\u2014Effects on treatment and immunogenicity.","volume":"7","author":"van Schie","year":"2015","journal-title":"MAbs"},{"issue":"3","key":"doi220027r18","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1080\/19420862.2018.1424610","article-title":"Development and characterization of an anti-rituximab monoclonal antibody panel.","volume":"10","author":"Tada","year":"2018","journal-title":"MAbs"},{"issue":"10","key":"doi220027r19","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1182\/blood-2003-01-0055","article-title":"Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia.","volume":"102","author":"Jilani","year":"2003","journal-title":"Blood"},{"issue":"1","key":"doi220027r20","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/exd.12299","article-title":"Lack of expression of an alternative CD20 transcript variant in circulating B cells from patients with pemphigus.","volume":"23","author":"Gamonet","year":"2014","journal-title":"Exp Dermatol"},{"key":"doi220027r14","doi-asserted-by":"crossref","unstructured":"Boyer-Suavet? S, Andreani? M, Lateb? M, . Neutralizing anti-rituximab antibodies and relapse in membranous nephropathy treated with rituximab. Accessed October 14, 2021. https:\/\/pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr\/31998325\/","DOI":"10.3389\/fimmu.2019.03069"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2793183\/jamadermatology_lemieux_2022_oi_220027_1659459487.45597.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T15:06:55Z","timestamp":1660921615000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2793183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2022.2149","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,1]]}}}